Is there any upside left for lxrx stock

Lexicon Pharmaceuticals (LXRX) has significant upside potential based on analyst ratings and price targets. Here's the analysis to support this conclusion:

1. Analyst Ratings and Price Targets:
   • LXRX has a strong buy consensus rating from analysts, with no hold or sell ratings in the past 3 months.
   • The average price target is $8.33, with a high estimate of $10.00 and a low estimate of $5.00.
   • This represents a 370.62% upside from the last price of $1.77.
2. Recent Positive Developments:
   • The FDA has accepted Lexicon's resubmitted NDA for Zynquista, which could lead to potential approval and market expansion.
   • The company has also announced strategic cost savings initiatives that could improve operational efficiency.
3. Technical Indicators:
   • The MACD is at 0.03, which could indicate a potential bullish trend.
   • The RSI is at 50.48, suggesting the stock is neither overbought nor oversold.
   • The stock is currently trading below its 5-day, 10-day, and 50-day moving averages, but these are all relatively close to the current price, indicating a tight range and potential for price movement.
4. Support and Resistance Levels:
   • The narrow support level is at $1.75, and the resistance level is at $1.8. The stock is currently trading close to the support level, which could be a point of interest for potential buyers.
5. Market Sentiment:
   • Despite a recent drop in stock price, there is a positive sentiment among analysts, with an average price target that suggests a significant upside.
   • The company's strategic initiatives and potential FDA approval could contribute to positive market sentiment.

In conclusion, Lexicon Pharmaceuticals (LXRX) has a strong buy consensus from analysts, with an average price target that indicates a substantial upside from the current price. The company's recent positive developments, technical indicators, and market sentiment all support the view that LXRX has significant growth potential.